Measurement of Lp (a) in the clinical setting contributes to the assessment of ASCVD risk,
and will become more important with the advent of specific Lp (a)-lowering therapies …

Abstract Purpose of Review Lipoprotein (a) is an independent risk factor for cardiovascular
disease. We review the ongoing shifts in consensus guidelines for the testing and …

Abstract Purpose of Review The purpose of this article is to review current evidence for
lipoprotein (a)(Lp (a)) as a risk factor for multiple cardiovascular (CV) disease phenotypes …

Abstract Elevated lipoprotein (a)(Lp [a]) is an independent, genetic risk factor for
atherosclerotic cardiovascular disease (ASCVD) that impacts~ 1.4 billion people globally …

Recent published studies have provided increasing evidence that lipoprotein (a)[Lp (a)] may
be a potential causal, genetic, independent risk factor for cardiovascular disease (CVD). Lp …

Abstract While lipoprotein (a)(Lp (a)) has long been an intriguing subject for basic
researchers and clinicians alike, it is only recently that this unique cardiovascular risk factor …

Introduction: Recent advances in genetics and epidemiology have once again thrust
lipoprotein (a)(Lp (a)) into the clinical spotlight. Elevated plasma concentrations of Lp (a) are …

High levels of lipoprotein (a)[Lp (a)] are causal for atherosclerotic cardiovascular disease
(ASCVD). Lp (a) is the most prevalent inherited dyslipidemia and strongest genetic ASCVD …

Recent advances in drug development aim to transi-tion lipoprotein (a)(Lp [a]) from a
predictive biomarker of cardiovascular disease to a therapeutic target. Among those with …

Abstract Lipoprotein (a)(Lp (a)) is a genetically determined causal risk factor for
cardiovascular disease including coronary heart disease, peripheral arterial disease …